Cargando…
Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma
Immune checkpoint inhibitors (ICIs) have been used as immunotherapeutic agents in several malignancies because of their ability to modify the T cell-mediated response against tumor cells. Dual checkpoint inhibition improves remission rates in patients with metastatic melanoma compared to monotherapy...
Autores principales: | Paparoupa, Maria, Stupperich, Sophie, Goerg-Reifenberg, Lisa, Wittig, Andreas, Schuppert, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670360/ https://www.ncbi.nlm.nih.gov/pubmed/33250697 http://dx.doi.org/10.1159/000511252 |
Ejemplares similares
-
Primary hypothyroidism resolves after switching from L‐thyroxine solid tablets to liquid oral substitution. A rare case without evidence of an underlying gastrointestinal malabsorption syndrome
por: Stupperich, Sophie, et al.
Publicado: (2022) -
Diffuse Metastatic Melanoma in the GI Lumen Following Immune Checkpoint Inhibitor Colitis Treatment
por: Sperling, Gabriel, et al.
Publicado: (2022) -
Hepatic Encephalopathy Is Not Always due to Liver Cirrhosis
por: Ecker, Miriam Eva, et al.
Publicado: (2022) -
A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects
por: Utsunomiya, Akira, et al.
Publicado: (2018) -
Immunochemotherapy - A Missed Opportunity for Metastasized Malignant Melanoma? Reporting a Therapeutic Success with Checkpoint Inhibitor Rechallenge after Cytotoxic Immuno-Priming in a Heavily Pretreated Patient
por: Kiderlen, Til R., et al.
Publicado: (2022)